Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17295140 | 0.87 | PTGS2 (0.41) | RAPGEF4PTGS2PTGS1LMNAPDE2A | |
| SCHEMBL391498 | 0.85 | RIPK1 (0.40) | RAPGEF4RIPK1PTGS2LMNATAAR1 | |
| SCHEMBL13219295 | 0.81 | RAPGEF4 (0.36) | RAPGEF4PTGS2PTGS1 | |
| SCHEMBL26676087 | 0.81 | PTGS2 (0.32) | RAPGEF4PTGS2PTGS1LMNATAAR1 | |
| SCHEMBL16521129 | 0.80 | RAPGEF4 (0.34) | RAPGEF4RIPK1 | |
| SCHEMBL15241715 | 0.79 | RAPGEF4 (0.35) | RAPGEF4PTGS2PTGS1 | |
| SCHEMBL14319055 | 0.79 | RAPGEF4 (0.35) | RAPGEF4PTGS2PTGS1 | |
| SCHEMBL21843886 | 0.79 | IDO1 (0.36) | RAPGEF4PTGS2PTGS1 | |
| SCHEMBL15823224 | 0.79 | ACHE (0.37) | RAPGEF4RIPK1PTGS2PTGS1 | |
| SCHEMBL21548743 | 0.77 | SKP2 (0.37) | RAPGEF4PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234925-A1 | GPR52 MODULATORS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-07-27 | — | — | US | disclosed |
| US-11014881-B2 | Hepatitis B capsid assembly modulators | VenatoRx Pharmaceuticals, Inc. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200123105-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | SPRING MILL PHARMA, INC. | 2020-04-23 | — | — | US | disclosed |
| WO-2007145922-A2 | BENZAZEPINONES AS SODIUM CHANNEL BLOCKERS | MERCK & CO., INC. (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200123105-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | HAVCR2, COPB1, HDLBP | RAPGEF4 1758/4885RIPK1 1362/4885PTGS2 3994/4885 |
| US-20230234925-A1 | GPR52 MODULATORS AND METHODS OF USE | GPR52, GPR68, GPR35 | RAPGEF4 367/4885RIPK1 3437/4885PTGS2 333/4885 |
| US-11014881-B2 | Hepatitis B capsid assembly modulators | HAVCR2, COPB1, HDLBP | RAPGEF4 1758/4885RIPK1 1362/4885PTGS2 3994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.